Inc. provided an update that further analyses from Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B agonist DNL343 in the treatment of amyotrophic lateral sclerosis did not ...

(Cell Reports) Topline results from a HEALEY platform trial showed that fosigotifator, an investigational eIF2B activator developed by the longevity company Calico Life Sciences in collaboration ...